SAN DIEGO — Entyvio therapy is safe for the long-term treatment of Crohn’s disease and ulcerative colitis, according to the final results of the GEMINI trial, presented at Digestive Disease Week.
“This is the longest study of continuous vedolizumab (Entyvio, Takeda) exposure to date,” Edward V. Loftus, Jr., MD, of the Mayo Clinic in Rochester, Minnesota, said in his presentation. “This looked at both safety and efficacy of vedolizumab for both UC and Crohn’s disease, and this is the final analysis of that data.”
There is no commercial support for this activity.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.